Program
Cholestyramine Resin
Also written as “Cholestyramine”, “cholestyramine” and “A3384”.
Its studies are mostly in Multiple Sclerosis · Hypercholesterolemia · Liver Cirrhosis, Biliary · Short Bowel Syndrome, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 61 open or running | phase 3since May 23, 2013 | May 23, 2013 | May 16, 2031phase 3 · NCT07930624 |
| Ipsen | 20 open or running | phase 2since Mar 3, 2014 | Mar 3, 2014 | none ahead |
| Eli Lilly | 10 open or running | phase 1since Jun 6, 2023 | Jun 6, 2023 | none ahead |
| Pharmascience | 10 open or running | phase 2since Jul 26, 2019 | Jul 26, 2019 | none ahead |
Also a collaborator on its studies: Regeneron Pharmaceuticals.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 23, 2013First study: phase 3 study in Multiple SclerosisNew to SanofiSanofi · NCT01863888 · 70 enrolled · Belgium, Germany, Netherlands
- Jan 23, 2014Phase 1 study in Multiple SclerosisSanofi · NCT02046629 · 12 enrolled · China
- Mar 3, 2014Ipsen's first study: phase 2 study in Bile Acid MalabsorptionNew to IpsenIpsen · NCT02078856 · 19 enrolled · Sweden, United Kingdom
- Aug 31, 2016Phase 2 study in HypercholesterolemiaSanofi · NCT02890992 · 42 enrolled · United States, Canada, Czechia and more
- Nov 1, 2016Phase 1 study in Liver Cirrhosis, BiliaryIpsen · NCT02963077 · 94 enrolled
- Apr 18, 20182 phase 3 studies in HypercholesterolemiaSanofi · NCT03510884, NCT03510715
- Jul 26, 2019Pharmascience's first study: phase 2 study in Short Bowel SyndromeNew to PharmasciencePharmascience · NCT04046328 · 13 enrolled · Poland
- Jun 6, 2023Eli Lilly's first study: phase 1 study in HealthyNew to Eli LillyEli Lilly · NCT05894928 · 21 enrolled · United States
- Nov 3, 2026Phase 3 study in Multiple SclerosisSanofi · NCT07930624 · 2,500 planned
Ahead
- May 16, 2031Primary completion: phase 3 study in Multiple SclerosisSanofi · NCT07930624
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07930624Multiple Sclerosis | 3 | Not yet recruiting | Sanofi | May 16, 2031 | 2,500 |
| NCT05894928Healthy · United States | 1 | Completed | Eli Lilly | Jul 9, 2023 | 21 |
| NCT04046328Short Bowel Syndrome · Poland | 2 | Terminated | Pharmascience | Dec 22, 2021 | 13 |
| NCT03510884Hypercholesterolemia · United States, Argentina, Austria and more | 3 | Completed | Sanofi | Jan 14, 2021 | 153 |
| NCT03510715Hypercholesterolemia · Brazil, Canada, Denmark and more | 3 | Completed | Sanofi | Feb 17, 2020 | 18 |
| NCT02963077Liver Cirrhosis, Biliary | 1 | Completed | Ipsen | May 2014 | 94 |
| NCT02890992Hypercholesterolemia · United States, Canada, Czechia and more | 2 | Completed | Sanofi | Sep 13, 2018 | 42 |
| NCT02078856Bile Acid Malabsorption · Sweden, United Kingdom | 2 | Completed | Ipsen | Dec 2014 | 19 |
| NCT02046629Multiple Sclerosis · China | 1 | Completed | Sanofi | Jul 2014 | 12 |
| NCT01863888Multiple Sclerosis · Belgium, Germany, Netherlands | 3 | Completed | Sanofi | Jan 2015 | 70 |
How it is read
Names in the registry
- “Cholestyramine”, 4 entries
- “cholestyramine”, 3 entries
- “A3384”, 1 entry
- “CRC (A3384)”, 1 entry
- “Questran”, 1 entry
Conditions, from the studies’ own filings
- Multiple Sclerosis, 3 studies
- Hypercholesterolemia, 3 studies
- Liver Cirrhosis, Biliary, 1 study
- Short Bowel Syndrome, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.